Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at November Investor Conferences

aTyr Pharma announces that it will present at two investor conferences in November 2023.
October 31, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD

aTyr Pharma announces that it has dosed the first patient in its Phase 2 EFZO-CONNECT study of efzofitimod in patients with SSc-ILD.
September 11, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...
August 24, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
August 09, 2023 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the...
June 22, 2023 08:00 ET | Source: aTyr Pharma, Inc.

European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis

SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
June 20, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference

Presentations highlight efzofitimod’s novel myeloid-cell focused mechanism and current Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis. SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma,...
June 09, 2023 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary...
June 06, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023)

Conference hosted by the International Union of Biochemistry and Molecular Biology (IUBMB) to feature leading research in tRNA synthetase biology. Presentations showcase company’s progress in...
May 25, 2023 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA...